TITLE

Shire drops 'emergency' Fabry's disease drug

AUTHOR(S)
Fox, Jeffrey L
PUB. DATE
June 2012
SOURCE
Nature Biotechnology;Jun2012, Vol. 30 Issue 6, p478
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on the biopharmaceutical company Shire's decision to withdraw its US marketing application for Replagal, an enzyme-replacement therapy for the treatment of Fabry's disease. It reports that Shire's decision to withdraw its application from the US Food and Drug Administration (FDA) came in context of Genzyme Corp's decision to resume the shipment of its own product, Fabrazyme, the only treatment approved in the U.S. for the treatment of Fabry's disease.
ACCESSION #
76403011

 

Related Articles

  • Shire Withdraws US Bid For Fabry Drug.  // MondayMorning;3/19/2012, Vol. 20 Issue 12, p1 

    The article presents information on Shire Pharmaceuticals Group Plc. which has withdrawn its bid for the drug Replagal Biologic, which is used to treat a genetic disorder called Fabry disease, for the U.S. Food and Drug Administration (FDA) approval. Shire has issued a statement according to...

  • pharmaceuticals In Brief.  // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p9 

    Reports on developments related to pharmaceutical industry in the U.S. as of January 10, 2005. Withdrawal of the new drug application of Supergen Inc. for Orathecin capsules; Approval of the U.S. Food and Drug Administration for Genzyme Corp.'s Clolar; License agreement between Shire...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;Sep2009, Vol. 8 Issue 9, p2 

    The article offers world news briefs related to the biotechnology industry. Pharmaceutical company Bristol-Myers Squibb Co. has agreed to acquire biopharmaceutical firm Medarex Inc. for 2.4 billion U.S. dollars. A fast track status has been given by the U.S. Food and Drug Administration (FDA) to...

  • FDA Panel to Examine Phosphate Binder Use. Young, Donna // BioWorld Today;10/15/2007, Vol. 18 Issue 200, p3 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to ask an advisory committee to investigate the appropriateness of using phosphate binders in predialysis patients for the treatment of hyperphosphatemia. Phosphate binders have been used in controlling serum...

  • Shire to submit new drug application to FDA for dry eye disease.  // Optometry Times;Jun2014, Vol. 6 Issue 6, p6 

    The article reports on the plan by pharmaceutical company Shire to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lifitegrast for the treatment of dry eye disease in adults in first-quarter 2015.

  • Genzyme wins big in small drug market. M.L. // Medical Marketing & Media;Jun2003, Vol. 38 Issue 6, p10 

    Reports on the U.S. Food and Drug Administration's approval of Genzyme General's Fabrazyme, an enzyme replacement therapy for Fabry's disease. Competition with Transkaryotic Therapies; Orphan drug status for Fabrazyme.

  • Antisense Comes of Age as Kynamro NDA in FDA Queue. Powers, Marie // BioWorld Today;5/30/2012, p1 

    The article reports that the new drug application (NDA) for Kynamro (mipomersen sodium) filed by Genzyme, a unit of Sanofi SA, has been accepted by the U.S. Food and Drug Administration (FDA). The first-in-class apolipoprotein B (Apo B) synthesis inhibitor will be evaluated for the treatment of...

  • Shire: Intuniv approval diversifies ADHD portfolio.  // PharmaWatch: CNS;Oct2009, Vol. 8 Issue 10, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Shire Pharmaceuticals Group PLC's non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD), Intuniv (guanfacine). The medication will be available in the U.S. pharmacies in November 2009 which...

  • COMPANY SPOTLIGHT - Shire Pharmaceuticals.  // PharmaWatch: CNS;Sep2005, Vol. 4 Issue 9, p17 

    This article presents information related to the business and research activities of Shire Pharmaceuticals Inc. The U.S. FDA has approved Shire's Adderall XR to be used in the treatment of attention deficit hyperactivity disorder in adolescents aged 13 to 17. The FDA based its approval on data...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics